Actively Recruiting

Age: 1Year - 18Years
All Genders
NCT05512169

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

Led by University of Geneva, Switzerland · Updated on 2026-01-15

556

Participants Needed

2

Research Sites

225 weeks

Total Duration

On this page

Sponsors

U

University of Geneva, Switzerland

Lead Sponsor

J

Jawaharlal Institute of Postgraduate Medical Education & Research

Collaborating Sponsor

AI-Summary

What this Trial Is About

A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva. The study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.

CONDITIONS

Official Title

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

Who Can Participate

Age: 1Year - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age > 1 year old and  years old at enrolment
  • Previously untreated
  • ALL diagnosis confirmed by morphology and flow-cytometry
  • Indian origins
  • Fulfilling IciCle treatment protocol inclusion criteria and receiving treatment as per the protocol
  • Written Informed consent to participate in the study has to be signed by the participant/parent/guardian
Not Eligible

You will not qualify if you...

  • Previously treated patients
  • Patients with Down's syndrome
  • Patients with mature B-ALL

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Dr. Sameer Bakhshi

New Delhi, India, 110029

Actively Recruiting

2

Dr. Biswajit Dubashi

Puducherry, India, 605006

Actively Recruiting

Loading map...

Research Team

C

Chakradhara Rao S Uppugudnuri

CONTACT

M

Marc Ansari

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here